/ 2 items

#BBIO↓

Featured/ BBIO/ 02/12/2026 · 8:08 AM

BridgeBio's Breakthrough: Oral Drug Succeeds in Dwarfism Study

BridgeBio's oral infigratinib outperforms BioMarin's injectable therapy in boosting growth for kids with achondroplasia, marking a major win in treating the genetic cause of dwarfism.

BBIO/ 10/29/2025 · 9:18 AM

BridgeBio's Encaleret Scores Major Win in Rare Calcium Disorder Trial

BridgeBio Pharma (BBIO) announces positive phase 3 results for encaleret in ADH1, showing 76% response rate. FDA filing planned for first half of 2026 alongside BBP-418 submission.